对老年冠心病合并高脂血症患者不同剂量阿托伐他汀治疗的临床研究

 目的探讨不同剂量阿托伐他汀对老年冠心病合并高脂血症患者进行强化降脂治疗的疗效及安全性.方法选择81例高脂血症患者,随机分为治疗组(阿托伐他汀,20 mg/d)和对照组(阿托伐他汀,10 mg/d),观察患者服药前及服药后6周及12周血脂、治疗达标率、主要不良心血管事件及药物不良反应.结果阿托伐他汀治疗后,两组TC、LDL-C、TG(除治疗6周时)水平均较治疗前显著减低(P＜0.01或P＜0.05),与对照组比较治疗组治疗6周及12周后,上述指标亦明显降低,差异有统计学意义(P＜0.05或P＜0.01).不同剂量阿托伐他汀在治疗6周和12周后TC、LDL-C达标率优于对照组(P＜0.05),且治疗组发生不稳定心绞痛者较对照组明显减少,差异有统计学意义(P＜0.05).结论阿托伐他汀20 mg/d可以显著提高血脂达标率,可明显降低主要心血管事件发生率,疗效与剂量相关.

Efficacy and safety of atorvastatin in treatment of hyperlipidemia in elderly patients with coronary heart diseases

Objective To evaluate the efficacy and safety of atorvastatin in different dosages for treatment of hyperlipidemia in elderly patients with coronary heart diseases.Methods Eighty-one patients with hyperlipidemia were randomized into higher dose group(atorvastatin,20 mg/d)and lower dose group(atorvastatin,10 mg/d).The levels of TC,LDL-C,TG and HDL-C in serum were examined,and cardiac events and side-effects of atorvastatin were observed before and after atorvastatin therapy.Results The levels of TC,LDL-C,TG(except for 6 weeks after treatment) in both groups were decreased significantly after treatment(P<0.01,P<0.05).After 6 weeks and 12 weeks of treatment,the levels of TC,LDL-C,TG in higher dose group were decreased more remarkedly than in lower dose group(P<0.05,P<0.01);there were significant differences in rates of reaching the standard between the two groups(P<0.05).The attacks of unstable angina pectoris in higher dose group were decreased,compared with the lower dose group(P<0.05).Conclusion Atorvastatin 20 mg/d is superior to atorvastatin 10 mg/d in reduction of TC,LDL-C,TG,and cardiac events.Atorvastatin is an effective and safe drug in treatment of the elderly patients with hyperlipidemia dose-dependently patients.